expert perspectives

in Non–Small Cell Lung Cancer

Expert Perspectives in Non–Small Cell Lung Cancer to Cover Key Topics in Non–Small Cell Lung Cancer Treatment

Overview

Expert Perspectives delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medicine, in a concise and timely format. This issue of Expert Perspectives in Non–Small Cell Lung Cancer will feature selected topics in Non–Small Cell Lung Cancer that we hope you will find of value in your clinical practice.

The clinicians who were surveyed selected the following experts and topics.

Community-Selected Experts:

Jeffrey Crawford, MD

George Barth Geller Professor for Research in Cancer
Duke University Medical Center
Lead PI of NCTN LAPS Grant
Duke Cancer Institute
Durham, NC

Bruce E. Johnson, MD

Chief Clinical Research Officer
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Gregory J. Riely, MD, PhD

Vice Chair, Clinical Research
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY


Community-Selected Topics:

Expert Roundtables 

    Beyond EGFR and ALK: Targeted Therapies for Non–Small Cell Lung Cancer
    Promising Research Directions: The Future of Non–Small Cell Lung Cancer Treatment
    Unmet Needs and Opportunities in Advanced Non–Small Cell Lung Cancer
    Combined Treatment Modalities for Older Patients With Advanced Non–Small Cell Lung Cancer

Clinical Topic Updates 

    Biomarkers for Response to Immune Checkpoint Inhibition
    Emerging Targets to Consider Including in a Larger Molecular Testing Panel
    Dual Targeting Strategies in Advanced Non–Small Cell Lung Cancer
    Adjuvant Immunotherapy in Non–Small Cell Lung Cancer

Patient Care Perspectives 

    Importance of Early Recognition of Actionable Mutations in Non–Small Cell Lung Cancer
    Immunotherapy Challenges: Immune-Related Adverse Events and Pseudoprogression
    Progression on Targeted Therapy for Non–Small Cell Lung Cancer: Best Practices
    Precision Therapies for Non–Small Cell Lung Cancer: Side Effects and Patient Education 

More in Non-Small Cell Lung Cancer

Thumb

Non-Small Cell Lung Cancer

Testing for Actionable Tumor Alterations in Non–Small Cell Lung Cancer

Clinical Topic Updates by Gregory J. Riely, MD, PhD

There are several critical molecular abnormalities that should be identified in all patients with non–small cell lung cancer (NSCLC). These include...READ MORE

Thumb

Non-Small Cell Lung Cancer

MEK Inhibition and Targeted Combinations for Advanced Lung Cancer

Clinical Topic Updates by Roy S. Herbst, MD, PhD

The identification of mutations in signaling pathways that are oncogenic has allowed the development of targeted therapies in the treatment of non–...READ MORE

Thumb

Non-Small Cell Lung Cancer

Imaging in the Era of Precision Therapy for Non–Small Cell Lung Cancer

Patient Care Perspectives by Bruce E. Johnson, MD

Imaging is valuable in assessing the disease at presentation and guiding targeted therapy with tyrosine kinase inhibitors (TKIs). Continued TKI the...READ MORE

More In Oncology

Non-Small Cell Lung Cancer

Biomarkers for Response to Immune Checkpoint Inhibition

Clinical Topic Updates
by Bruce E. Johnson, MD

Non-Small Cell Lung Cancer

Newer Targets and Therapies for Non–Small Cell Lung Cancer

Expert Roundtables
by Jeffrey Crawford, MD; Bruce E. Johnson, MD; and Gregory J. Riely, MD, PhD